Genmab A/S (NASDAQ:GMAB) Shares Gap Up – What’s Next?

Genmab A/S Sponsored ADR (NASDAQ:GMAB)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $26.02, but opened at $27.96. Genmab A/S shares last traded at $27.73, with a volume of 727,351 shares traded.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research reports. Truist Financial assumed coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. Wolfe Research started coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target on the stock. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.93.

Genmab A/S Trading Up 6.0%

The company has a market cap of $17.19 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 1.66 and a beta of 0.85. The company’s 50 day simple moving average is $26.18 and its two-hundred day simple moving average is $28.75. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its holdings in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. increased its stake in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of Genmab A/S during the first quarter worth about $34,000. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.